Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Jennifer Leddon
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07385846CT.gov Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency | — | Not Yet Recruiting | — | — | — |
NCT07301268CT.gov GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma | — | Recruiting | — | — | — |
NCT07410676CT.gov EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06749925CT.gov Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma | — | Not Yet Recruiting | — | — | — |
NCT07347210CT.gov Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma | — | Not Yet Recruiting | — | — | — |
NCT06894225CT.gov Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature | — | Suspended | — | — | — |
NCT06556563CT.gov EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | — | Recruiting | — | — | — |
NCT06558214CT.gov OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial | — | Recruiting | — | — | — |
NCT06640582CT.gov TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas | — | Recruiting | — | — | — |
NCT05879120CT.gov Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | — | Withdrawn | — | — | — |
Show 31 more trialsShow fewer
NCT05973903CT.gov Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | — | Withdrawn | — | — | — |
NCT06157541CT.gov T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma | — | Recruiting | — | — | — |
NCT05700955CT.gov Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma | — | Unknown | — | — | — |
NCT05463848CT.gov Surgical Pembro +/- Olaparib w TMZ for rGBM | — | Recruiting | — | — | — |
NCT05235737CT.gov The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab | — | Unknown | — | — | — |
NCT05084430CT.gov Study of Pembrolizumab and M032 (NSC 733972) | — | Recruiting | — | — | — |
NCT04977375CT.gov Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | — | Recruiting | — | — | — |
NCT04118036CT.gov Abemaciclib + Pembrolizumab In Glioblastoma | — | Withdrawn | — | — | — |
NCT05053880CT.gov A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | — | Active Not Recruiting | — | — | — |
NCT04913337CT.gov Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT03899857CT.gov Pembrolizumab for Newly Diagnosed Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT04479241CT.gov LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma | — | Completed | — | — | — |
NCT04013672CT.gov Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | — | Completed | — | — | — |
NCT04201873CT.gov Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT04121455CT.gov Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients | — | Active Not Recruiting | — | — | — |
NCT03726515CT.gov CART-EGFRvIII + Pembrolizumab in GBM | — | Completed | — | — | — |
NCT03797326CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | — | Completed | — | — | — |
NCT03722342CT.gov TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma | — | Unknown | — | — | — |
NCT03665545CT.gov Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma | — | Completed | — | — | — |
NCT03661723CT.gov Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | — | Completed | — | — | — |
NCT03426891CT.gov Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | — | Completed | — | — | — |
NCT03405792CT.gov Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) | — | Active Not Recruiting | — | — | — |
NCT03197506CT.gov Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT03347617CT.gov Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma | — | Terminated | — | — | — |
NCT03018288CT.gov Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) | — | Terminated | — | — | — |
NCT02798406CT.gov Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | — | Completed | — | — | — |
NCT02337686CT.gov Pembrolizumab in Treating Patients With Recurrent Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT02337491CT.gov Pembrolizumab +/- Bevacizumab for Recurrent GBM | — | Completed | — | — | — |
NCT02287428CT.gov Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM | — | Active Not Recruiting | — | — | — |
NCT01814813CT.gov Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT03311542CT.gov Expanded Access for Pembrolizumab (MK-3475) | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Jennifer Leddon | Approved | B · 62 |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Capecitabine | Northwell Health | P2 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Carboplatin | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →